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RESEARCH ARTICLE

Suppression of β3-integrin in mice triggers a neuropilin-1dependent change in focal adhesion remodelling that can
be targeted to block pathological angiogenesis

ABSTRACT
Anti-angiogenic treatments against αvβ3-integrin fail to block
tumour growth in the long term, which suggests that the tumour
vasculature escapes from angiogenesis inhibition through αvβ3integrin-independent mechanisms. Here, we show that suppression
of β3-integrin in mice leads to the activation of a neuropilin-1 (NRP1)dependent cell migration pathway in endothelial cells via a mechanism
that depends on NRP1’s mobilisation away from mature focal
adhesions following VEGF-stimulation. The simultaneous genetic
targeting of both molecules significantly impairs paxillin-1 activation
and focal adhesion remodelling in endothelial cells, and therefore
inhibits tumour angiogenesis and the growth of already established
tumours. These findings provide a firm foundation for testing drugs
against these molecules in combination to treat patients with advanced
cancers.
KEY WORDS: Integrin, Neuropilin-1, Angiogenesis, Tumour,
Focal adhesion

INTRODUCTION

Angiogenesis, the formation of new blood vessels from pre-existing
vasculature, is essential to support both primary and metastatic
tumour growth (Hanahan and Weinberg, 2011). It occurs when
hypoxia causes tumour cells to release growth factors such as
vascular endothelial growth factor (VEGF), which stimulate nearby
endothelial cells (ECs) to activate appropriate growth factor
receptors, e.g. VEGF-receptor-2 (VEGFR2). New blood-vessel
formation ensues as ECs proliferate and migrate through the
extracellular matrix (ECM) toward the tumour in an integrindependent fashion (Robinson and Hodivala-Dilke, 2011). This
process of tumour angiogenesis frequently offers a route to
metastasis by providing an increased density of highly permeable
blood vessels. Thus, anti-angiogenic strategies form a key
component of the current cancer-targeting arsenal. Because of its
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central role in the process, many of the existing anti-angiogenic
strategies target the VEGF-VEGFR2 pathway, but these approaches
are linked to a plethora of unwanted side effects and the
development of treatment resistance (Ebos and Kerbel, 2011).
Integrins are the main ECM adhesion receptors. They sense,
integrate and disseminate ECM and growth factor signals to coordinate EC responses during angiogenesis (Silva et al., 2008).
αvβ3-integrin has emerged as a key anti-angiogenic therapeutic
target because it is upregulated in the vasculature of solid tumours,
but its expression is low in quiescent vasculature (Brooks et al.,
1994). Unlike current FDA-approved anti-angiogenic drugs,
αvβ3-integrin antagonists are well-tolerated, likely owing to the
fact that αvβ3-integrin expression is restricted to neo-angiogenic
vessels (Hariharan et al., 2007). However, the synthetic inhibitors
directed against αvβ3-integrin have so far failed to improve overall
survival in patients (Marelli et al., 2013). Moreover, although we
have shown that suppressing endothelial αvβ3-integrin in the early
stages of tumour growth has an inhibitory growth effect, its longterm suppression leads to ‘treatment’ resistance (Steri et al., 2014).
We do not yet understand what the mechanisms of resistance are, or
how to overcome them. In order to improve therapeutic outcomes
when targeting this key molecule, we need to rethink how to best
use anti-angiogenic strategies based on αvβ3-integrin antagonism.
A promising approach to overcome resistance to anti-angiogenic
treatment is to identify pathways of resistance and to co-target them
alongside the original target. Such approaches are emerging in a
number of cancer types as viable therapeutic strategies to improve
upon existing treatments (Sennino and McDonald, 2012). In 2009,
an αvβ3-integrin co-target candidate emerged: the VEGF coreceptor, neuropilin-1 (NRP1) (Robinson et al., 2009). However, we
do not yet fully understand how these two molecules cooperate
mechanistically to regulate pathological angiogenesis, nor do we
know whether their interaction can be manipulated to alter
outcomes.
NRP1 is a single-pass transmembrane molecule found, for
example, in neurons and ECs. Originally identified as an adhesion
molecule (Takagi et al., 1995), attention shifted to its VEGFdependent role in binding and regulating the signalling and
trafficking of VEGFR2 in ECs (Ballmer-Hofer et al., 2011;
Herzog et al., 2011). NRP1’s short cytoplasmic tail is crucial for
the regulation of VEGFR2 trafficking because its SEA motif binds
the PDZ domain of synectin, linking the complex to the inward
trafficking motor myosin VI (Ballmer-Hofer et al., 2011; Cai and
Reed, 1999). Recent work has returned to its original role as
an adhesion molecule. Valdembri et al. (2009) showed that
NRP1 binds and regulates α5β1-integrin trafficking, again via its
cytoplasmic tail, and thus promotes EC spreading on low
1105
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TRANSLATIONAL IMPACT
Clinical issue
αvβ3-integrin has emerged as a key anti-angiogenic target in cancer
therapy because it plays a pivotal role in endothelial cell migration and
vascular endothelial growth factor (VEGF)-mediated signalling.
However, innate and acquired treatment resistance occurs with its
blockade, so treatment fails to block tumour growth in the long term.
Understanding the molecular mechanisms that contribute to this
resistance is necessary for developing new strategies that target αvβ3integrin to inhibit tumour growth and progression. It is clear that
alternative pro-angiogenic pathways become active in the absence of
αvβ3-integrin expression, which suggests that these pathways offer
routes to resistance to αvβ3-integrin blockade. This study seeks to
understand the molecular basis behind how αvβ3-integrin-regulated
pathways contribute to anti-angiogenic resistance and to test the
hypothesis that blocking αvβ3-integrin in combination with these
pathways will block tumour progression.
Results
Using heterozygous β3-integrin-deficient mice as a model of αvβ3-integrin
blockade, the authors uncovered a neuropilin-1 (NRP1)-regulated
endothelial-cell-migration pathway that only becomes active when αvβ3integrin expression is suppressed. In β3-integrin heterozygous endothelial
cells, but not in wild type, NRP1 regulated paxillin-1 phosphorylation, focal
adhesion remodelling and cell migration. This newly found role for NRP1
correlates with its mobilisation away from mature focal adhesions in
VEGF-induced β3-integrin-depleted cells; this shift in cellular localisation
does not occur in wild-type cells. Finally, the authors show that
suppressing the endothelial expression of both αvβ3-integrin and NRP1
blocks the progression of already-established tumours.
Implications and future directions
This study uncovered an NRP1-dependent migration pathway that only
becomes active upon αvβ3-integrin depletion and it showed that this
pathway can be targeted to block tumour progression. These results
implicate endothelial NRP1 as a potential co-target during αvβ3-integrindirected therapies to prevent anti-angiogenic treatment resistance.

concentrations of fibronectin (FN), whereas Raimondi et al. (2014)
demonstrated an essential role for NRP1 in promoting FNdependent signalling in ECs. In support of VEGF-independent
roles for NRP1 in ECs, Fantin et al. (2014) found that mice with a
mutant NRP1 defective in VEGF binding overcome the midgestation lethality of full NRP1-knockout mice (Kawasaki et al.,
1999). Indeed, there is mounting evidence that links VEGFindependent roles for NRP1 to focal adhesion (FA) function
(Raimondi et al., 2014; Seerapu et al., 2013). What we do not yet
know is how and when, and in what cell types, NRP1 contributes to
the assembly and maintenance of these large and dynamic
macromolecular assemblies that link the ECM to the cytoskeleton
and through which both mechanical force and regulatory signals are
transmitted (Zamir and Geiger, 2001).
That NRP1 plays a crucial role in developmental angiogenesis
and arteriogenesis is undeniable (Fantin et al., 2014, 2011; Gerhardt
et al., 2004; Kawasaki et al., 1999; Lanahan et al., 2013), but its role
in pathological angiogenesis is not clear. Although a number of
papers allude to it having no role, Fantin et al. (2014) published
findings suggesting that the VEGF-binding domain of NRP1 is
important for pathological neovascularisation of the retina and
angiogenesis-dependent tumour growth. Here, we conclusively
show, however, that disrupting NRP1 function by deleting its
cytoplasmic tail or by depleting its expression in wild-type mice has
no effect on tumour growth or angiogenesis. However, we can
sensitise angiogenic responses to NRP1 perturbations by reducing
1106
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β3-integrin expression in heterozygous β3-integrin-deficient mice.
We show that β3-integrin expression is essential for the efficient
retention of NRP1 at FAs after VEGF-stimulation. NRP1 can
influence paxillin-1 (PXN) activity and FA remodelling, but only if
it is relieved from its retention within mature FAs by reducing β3integrin expression. This sensitisation to NRP1 perturbations that
occurs upon suppressing β3-integrin means that we can target both
molecules simultaneously to significantly improve inhibition of
growth and angiogenesis in both new and established tumours. This
finding offers a potential solution to improve anti-angiogenic
strategies.
RESULTS
Pathological angiogenesis is sensitive to NRP1 disruption in
heterozygous β3-integrin-deficient mice

We previously showed that VEGF-mediated angiogenic responses
become dependent on NRP1 in β3-integrin-knockout (β3-KO) mice
(Robinson et al., 2009). In this model, angiogenesis was
significantly blocked only by simultaneously inhibiting both β3integrin and NRP1, a finding that we would like to translate to the
clinic. In the β3-KO model, however, pathological angiogenesis is
elevated over the wild type (Reynolds et al., 2002). It has been
postulated that this phenotypic response occurs, in part, through the
developmental upregulation of VEGFR2 (Reynolds et al., 2004),
making it potentially difficult to interpret experimental outcomes
that depend on molecular interactions with this growth-factor
receptor. We therefore moved our analyses to β3-integrinheterozygous (β3-HET) mice, hypothesising that this would
circumvent developmental changes arising from the complete loss
of the protein, whilst at the same time maintaining, at least to a
degree, critical interactions between β3-integrin and VEGFR2
(Mahabeleshwar et al., 2007) and/or NRP1 (Robinson et al., 2009).
We crossed β3-integrin-wild-type (β3-WT) and β3-HET mice to
tamoxifen (OHT)-inducible Pdgfb-iCreERT2/NRP1-floxed mice
(Claxton et al., 2008; Gu et al., 2003) and examined the effect of
an acute EC-specific depletion of NRP1 (EC-NRP1-KO) on
subcutaneous allograft tumour growth with both CMT19T cells
(Fig. 1A) and B16F0 cells (supplementary material Fig. S1), as well
as on aortic ring sprouting (Fig. 1B). Depleting EC-NRP1 expression
in this way had no effect on β3-WT responses, but significantly
inhibited tumour growth and VEGF-induced microvessel sprouting
in β3-HET mice. Tumour angiogenesis was significantly inhibited in
β3-HET mice by depleting EC-NRP1, although vessel morphology
and pericyte coverage were normal (Fig. 1C). These studies are
reminiscent of the changes observed in β3-KO mice, but,
importantly, suggest that NRP1 function is already perturbed by
subtle changes in β3-integrin expression levels.
To narrow our mechanistic focus further, we crossed β3-WT and
β3-HET animals with mice carrying a global deletion of NRP1’s
cytoplasmic tail (NRP1Δcyto), which is essential for many of its
functions (Fantin et al., 2011; Lanahan et al., 2013). CMT19T
tumour growth (Fig. 1D) and microvessel sprouting (Fig. 1E)
patterns were unaltered in β3-WT mice by the introduction of the
NRP1Δcyto mutation, whereas both parameters were inhibited in
β3-HET mice. Although the loss of NRP1’s cytoplasmic tail had a
small effect on tumour angiogenesis in β3-WT mice (Fig. 1F), this
did not translate to an overall difference in tumour growth (Fig. 1D).
As in EC-NRP1-KO tumours, pericyte coverage of tumour
vasculature was not affected by an NRP1 cytoplasmic deletion
(Fig. 1F). We conclude from these studies that NRP1’s cytoplasmic
tail is normally dispensable for pathological angiogenesis, but plays
a significant role when insufficient β3-integrin is expressed.
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Fig. 1. Tumour growth, tumour angiogenesis and microvessel sprouting in β3-integrin-deficient heterozygous mice are sensitive to NRP1
perturbations. (A) Tumour growth was measured in animals of the indicated genotypes. Mice were given subcutaneous injections of CMT19T tumour cells. To
generate NRP1-EC-KO (EC-null), 21-day slow-release OHT pellets were administered 3 days prior to tumour-cell injection. OHT-treated Cre-negative (NRP-ECWT) littermates served as controls. Tumour volumes were measured after 12 days of growth (mean+s.e.m. of three independent experiments; n≥10 animals per
genotype). Representative pictures of tumour macroscopic appearances are shown. Scale bar: 10 mm. (B) Microvessel sprouting of aortic ring explants of the
indicated genotypes. NRP1-EC-KO was induced in culture with 1 μM OHT. OHT-treated Cre-negative (EC-NRP-WT) rings served as controls. The bar chart
shows the total number of microvessel sprouts per aortic ring after 6 days of VEGF-stimulation (mean+s.e.m. from three independent experiments; n≥40 rings per
genotype). (C) Blood-vessel density was assessed in tumours of the indicated genotypes by counting the total number of endomucin-positive vessels across
tumour sections (mean+s.e.m.; n≥10 sections per genotype over three independent experiments). Representative micrographs of immunofluorescence staining
for endomucin, an endothelial cell marker (Endo; red) and CD146, a pericyte marker (green) in tumour sections from each genotype are shown. DAPI (blue) was
used as a nuclear counterstain. Scale bar: 100 μm. (D) CMT19T tumour growth and angiogenesis were measured in animals of the indicated genotypes. In
addition to their β3-integrin genetic status, mice were negative (NRP1 WT) or positive (NRP1 Δcyto) for the loss of NRP1’s cytoplasmic tail. Mice were given
subcutaneous injections of CMT19T cells and tumour volumes were measured 12 days later. The bar chart shows tumour volumes (mean+s.e.m. of three
independent experiments; n≥10 animals per genotype). (E) Microvessel sprouting of aortic ring explants of the indicated genotypes. The bar chart shows the total
number of microvessel sprouts per aortic ring after 6 days of VEGF-stimulation (mean+s.e.m. from three independent experiments; n≥40 rings per genotype).
(F) Blood-vessel density was assessed by endomucin (red) and CD146 (green) staining (mean+s.e.m.; n≥10 sections per genotype). DAPI was used as a
nuclear counterstain (blue). Scale bar: 100 μm. Asterisks indicate statistical significance: *P<0.05; **P<0.01; ***P<0.001; nsd, not significantly different. Unpaired
two-tailed t-test.

NRP1-dependent functions of VEGFR2 are normal in
β3-integrin-heterozygous endothelial cells

Given that NRP1’s cytoplasmic tail is important for the regulation of
VEGFR2 signalling and trafficking (Ballmer-Hofer et al., 2011;
Herzog et al., 2011), we wanted to investigate whether the
NRP1Δcyto mutation differentially affects VEGFR2 function in
β3-WT versus β3-HET lung microvascular ECs. We employed
polyoma-middle-T-antigen immortalised ECs, isolated from the
mutant mice described above, because we and others have shown
that they present good models to study angiogenesis (Ni et al., 2014;

Robinson et al., 2009; Steri et al., 2014; Tavora et al., 2014). We first
compared total VEGFR2 levels in the four genotypes (β3-WT,
β3-HET, β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto). Unlike
β3-KO ECs, we noted only a small trend of increased VEGFR2
levels in β3-HET and β3-HET;NRP1Δcyto ECs (Fig. 2A).
To explore potential changes in VEGFR2-dependent signalling,
we seeded ECs on a complex matrix containing gelatin, collagen I
(COLI), FN and vitronectin (VN) to preserve the known
VN-dependent β3-VEGFR2 interaction (Soldi et al., 1999),
stimulated with VEGF, and immunoblotted for changes in total
1107
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Fig. 2. NRP1-dependent functions of VEGFR-2 are normal in β3-integrin-heterozygous endothelial cells. (A) Lung microvascular endothelial cells (ECs)
were isolated and immortalised ( polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either normal (WT NRP1) or cytoplasmic-taildeleted (NRP1 Δcyto) NRP1. Multiple EC lysates of each genotype were western blotted (WB) to examine total cellular levels of VEGFR2 and β3-integrin. Bar
charts of densitometric analysis of mean (+s.e.m.) changes between the four genotypes are shown to the right. Asterisks indicate statistical significance: *P<0.05.
(B-E) Representative of ≥three independent experiments per blotted protein. ECs were seeded overnight on a complex matrix containing gelatin, collagen,
fibronectin and vitronectin, and were then stimulated with VEGF over the indicated time courses. (B) ECs were lysed and blotted for levels of phosphorylated
( phospho) and total VEGFR2, NRP1, and phospho ( pERK) and total (tERK) ERK1/2. (C) To examine protein degradation, the VEGF time course was extended
and EC lysates were blotted for levels of total VEGFR2, NRP1 and β3-integrin. (D) Following a VEGF time course, ECs were trypsinised and analysed by flow
cytometry for surface levels of VEGFR2. Median fluorescence intensity was measured after forward versus side scatter data were tightly gated around, and
normalised to, an isotype control. The graph shows the relative surface level of VEGFR2 (means±s.e.m.) relative to the 0 (non-stimulated) time point. (E) ECs were
stimulated with VEGF for the indicated amounts of time and then lysed and immunoprecipitated for VEGFR2 (VEGFR2 IP), before being blotted for NRP1
association. A total cell lysate (TCL) is shown for comparison. (A-E) HSC-70 served as a loading control. Data are representative of three independent
experiments.
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and phosphorylated levels of VEGFR2 and its downstream targets
ERK1/2 (Koch et al., 2011) (Fig. 2B). Although VEGF-induced
VEGFR2 phosphorylation was slightly elevated in β3-HET ECs,
VEGFR2 phosphorylation was not significantly changed by the
introduction of the NRP1Δcyto mutation in either β3-WT or
β3-HET ECs, suggesting that VEGFR2 signalling is NRP1independent in these microvascular ECs despite differences in
β3-integrin expression. In contrast, VEGF-induced ERK1/2
phosphorylation was sensitive to an NRP1 cytoplasmic deletion
in β3-HET ECs but not β3-WT ECs (Fig. 2B).
We observed no overt changes in the pattern of total cellular
VEGFR2 expression over time after VEGF stimulation when
comparing the four genotypes to one another (Fig. 2C). In each
case, VEGFR2 expression levels dropped over the time course of
stimulation. This is suggestive of the protein being degraded over time
in all four genotypes and is congruent with prior reports (Ewan et al.,
2006; Reynolds et al., 2009; Reynolds and Hodivala-Dilke, 2006).
Taken together, these signalling studies pointed to a VEGFR2independent role for NRP1 in mediating VEGF-induced responses
in β3-HET ECs. However, as previously mentioned, when
compared to their β3-WT counterparts, total VEGFR2 levels were
slightly elevated in both β3-HET and β3-HET;NRP1Δcyto ECs.
Moreover, NRP1 expression was substantially increased in both
β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto ECs (Fig. 2A,B). We
therefore decided to examine VEGFR2 behaviour in greater detail,
including its direct interactions with NRP1.
We measured VEGFR2 surface levels via flow-cytometry over a
VEGF-stimulated time course (Fig. 2D). However, surface levels
were similar between the four genotypes, and were as predicted
from previously published studies (Lampugnani et al., 2006;
Reynolds et al., 2009). Because VEGF-induced interactions
between VEGFR2 and NRP1 are elevated in β3-KO ECs
(Robinson et al., 2009), we next examined this interaction in
β3-HET ECs by co-immunoprecipitation, but observed no
alterations compared to β3-WT ECs (Fig. 2E). In contrast to
previously published studies (Prahst et al., 2008), we saw that the
VEGF-induced association between the two molecules was
preserved in both β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto
ECs (Fig. 2E). We also examined by immunoblotting other known
NRP1-dependent signalling pathways, including the activation of
focal adhesion kinase (FAK) (Herzog et al., 2011) and p130Cas
(Evans et al., 2011), but saw no changes that might explain why
β3-HET mice are sensitive to NRP1 perturbation, whereas β3-WT
mice are not (supplementary material Fig. S2); both pathways were
inhibited in both genotypes by the introduction of the NRP1Δcyto
mutation.
Although these analyses did not rule out subtle differences
between the four genotypes in VEGFR2 trafficking, they did allow
us to draw an important conclusion: the differential sensitivity of
β3-WT and β3-HET animals to NRP1 disruption does not seem to
arise from overt changes in VEGFR2 function.
The VEGF-induced migration in β3-integrin-heterozygous
microvascular endothelial cells depends on the cytoplasmic
tail of NRP1

Prior to its description as a VEGF co-receptor, NRP1 was identified
as a surface protein mediating cell adhesion (Takagi et al., 1995).
Moreover, evidence has mounted to support a VEGFR2independent role for NRP1 in regulating EC functions through an
FA-dependent mechanism (Fantin et al., 2014; Raimondi et al.,
2014; Seerapu et al., 2013). Because NRP1 is known to interact with
a number of integrins (Fukasawa et al., 2007; Robinson et al., 2009;

Disease Models & Mechanisms (2015) 8, 1105-1119 doi:10.1242/dmm.019927

Valdembri et al., 2009), we first compared static cell adhesion
between β3-WT, β3-HET, β3-WT;NRP1Δcyto and β3-HET;
NRP1Δcyto ECs on saturating concentrations of various matrices.
The only clear difference noted on saturating matrix concentrations
in these assays was an expected reduced adhesion of β3-HET and
β3-HET.NRP1Δcyto ECs to matrices containing VN, β3-integrin’s
canonical ligand (Fig. 3A). A more vigorous examination of
adhesions (see Materials and Methods) over a range of matrix
concentrations, however, uncovered subtle changes between the
genotypes (Fig. 3B). Not surprisingly, compared to β3-WT and
β3-WT;NRP1Δcyto ECs, β3-HET and β3-HET;NRP1Δcyto ECs
showed reduced adhesion to VN over a range of concentrations
tested. β3-WT;NRP1Δcyto EC adhesion to FN was, as expected
(Valdembri et al., 2009), somewhat reduced compared to β3-WT
ECs. Compared to their WT counterparts, β3-HET and β3-HET;
NRP1Δcyto ECs exhibited reduced strength of adhesion to FN over
the gradient of concentrations tested.
We therefore used flow-cytometry to examine the surface
expression of various EC integrin subunits (Fig. 3C). Consistent
with the adhesion data, αv- and β3-integrin levels were significantly
higher in β3-WT and β3-WT;NRP1Δcyto ECs compared to their
β3-HET counterparts. Whereas α1, β1 and β5 surface levels were
unchanged, we noted a small increase in α2 surface expression in
β3-HET ECs. Most notably, however, α5-integrin surface levels
were lower in ECs expressing reduced levels of β3-integrin (Fig. 3C),
which might partially account for their reduced adhesion to FN.
Our observations of VEGFR2-independent changes in ERK1/2
phosphorylation (a known regulator of integrin-mediated migration)
that were nonetheless sensitive to alterations in NRP1 function in
β3-HET but not β3-WT ECs prompted us to examine whether cell
migration was differentially dependent on NRP1 upon reduced
levels of β3-integrin expression. Because NRP1, α5β1-integrin and
αvβ3-integrin all promote adhesion to FN (Hynes, 2002; Valdembri
et al., 2009), we next set out to measure migration on this matrix
component. In light of noted subtle differences in short-term
adhesion to FN (and in surface expression of α5-integrin), we first
tested long-term cell spreading of our four cell lines to 10 µg/ml FN,
a saturating concentration which effectively promotes cell adhesion
and migration (Clark et al., 1986; Sottile et al., 1998; Tvorogov
et al., 2005). Cell spreading after 6 h was similar in all four
genotypes (Fig. 3D). This, along with our static adhesion assays,
which showed no differences between the genotypes on this
concentration of the matrix, provided justification for examining
random (Fig. 3E) and directed (Fig. 3F) migration in cells plated
long-term (overnight) on this concentration of FN. Both types of
migration assays revealed enhanced baseline and VEGF-induced
migration in β3-HET ECs, compared to β3-WT ECs; unlike β3-WT
ECs, β3-HET ECs were sensitive to NRP1 disruption.
NRP1’s localisation to focal adhesions is altered in
β3-integrin-heterozygous endothelial cells

The findings described above suggested that aberrant integrindirected migration, essential for pathological angiogenesis,
correlates with the phenotypic difference in sensitivity to NRP1
perturbations that we observed in β3-HET mice. NRP1 is known to
colocalise with a number of FA-associated proteins (Seerapu et al.,
2013) and is involved in FA turnover. We therefore took a closer
look at the structural and functional characteristics of mature
endothelial FAs, focal points of cellular migration. We first
examined NRP1’s distribution in subcellular compartments after
cell fractionation and immunoblotting. Other than the previously
noted trend toward overexpression of the protein in β3-HET ECs, we
1109
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Fig. 3. VEGF-induced migration in β3-integrin-heterozygous endothelial cells is dependent on NRP1. (A) ECs isolated from animals of the four
indicated genotypes were seeded on collagen type I (COLI), fibronectin (FN), laminin (LN), vitronectin (VN), or a complex mixture of COLI, FN, VN and
gelatin (MIX) for 90 min. Unattached cells were gently washed off, and the remaining cells were fixed and stained. Dye was extracted and measured
spectophotometrically. The bar chart shows the percentage of cell adhesion to each component relative to FN (means+s.e.m. from three independent
experiments). (B) ECs of the indicated genotypes were plated on increasing concentrations of FN or VN. After 90 min, plates were vigorously washed and
remaining cells were fixed and stained. Dye was extracted and measured spectophotometrically. The graph shows the mean (±s.e.m. from ≥two independent
experiments) number of cells that remained attached to the plate after the procedure. (C) ECs of the indicated genotypes were measured for their surface
expression of endothelial integrin subunits by flow cytometry. Median fluorescence intensity (MFI) was measured after forward versus side scatter data were
tightly gated around, and normalised to, an isotype control. The bar chart shows the relative change in MFI of β3-HET compared to β3-WT ECs, or of β3-HET.
NRP1Δcyto ECs compared to β3-WT.NRP1Δcyto ECs (means+s.e.m. from three independent experiments). Relative changes were deemed significant with a
twofold change. Representative flow-cytometric histogram profiles are shown below for significantly changed integrins. (D) 70×105 cells of the indicated
genotypes were plated for 6 h on 10 μg/ml FN in six-well plates. Phase-contrast photographs were taken and cell surface areas were measured using ImageJ™
software. The bar chart represents mean (+s.e.m.) surface area quantified from multiple images (n≥50 cells per genotype). (E) ECs were firmly attached to
FN-coated dishes and then imaged live for 15 h in low-serum medium ±VEGF. Individual cells were tracked every 10 min over this period using ImageJ™. The bar
chart shows the EC migration speed of each of the indicated genotypes (mean+s.e.m. from three independent experiments; n=50 cells per condition). (F) ECs
were plated onto FN-coated dishes overnight. After 3 h of starvation, a scratch wound was created and cells were incubated in low-serum medium ±VEGF for 24 h.
The bar chart shows the percentage closure of the scratch ‘wound’ as a result of directed cell migration (means+s.e.m. from three independent experiments; n=27
for each condition). Representative images of scratch-wound closure at 24 h are shown below. Scale bar: 200 μm. Asterisks indicate statistical significance:
*P<0.05; **P<0.01; ***P<0.001; nsd, not significantly different. Unpaired two-tailed t-test.
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Fig. 4. NRP1’s localisation in focal adhesions is altered in β3-integrin-heterozygous endothelial cells. (A) β3-WT and β3-HET ECs were subjected to a
cell-fractionation experiment following ±VEGF treatment for 10 min. Fractionated samples were then analysed by western blot for the indicated proteins.
1=cytoplasmic extract; 2=membrane extract; 3=soluble nuclear extract; 4=chromatin-bound nuclear extract; 5=cytoskeletal extract. Protein markers for each
subcellular compartment were included as controls. Data are representative of two independent experiments. The bar charts represent the relative proportion (%)
of VEGFR2 or NRP1 present in each fraction determined by ImageJ™ densitometry. (B) Left and right panels: β3-WT and β3-HET ECs were seeded overnight
onto FN-coated glass coverslips and then stimulated with VEGF for 10 min. Cells were fixed and stained with phalloidin for filamentous actin (F-actin; green), and
immunostained for neuropilin-1 (NRP1; red). Arrows point to the ends of actin filaments. Middle panel: β3-WT ECs were transfected with a β3-integrin-GFP
construct (green) and seeded on FN-coated coverslips. 48 h later, cells were fixed and immunostained for NRP1 (red). Split-channel close-ups are shown to
depict β3-integrin/NRP1 colocalisation. Scale bars: 10 μm (middle), or 20 μm. (C) ECs were allowed to adhere to FN-coated dishes for 90 min to establish ‘mature’
integrin-dependent focal adhesions (FAs). FAs were chemically cross-linked to the plates and cells were lysed with RIPA buffer. Non-cross-linked proteins and
other cellular components were rinsed away under high-sheer flow. FA-enriched complexes were eluted, subjected to SDS-PAGE and then analysed by labelfree, quantitative mass spectometry. The graphs represent log ratio plots of the proteomic data comparing unstimulated β3-WT ECs ( y-axis) and β3-HET ECs
(x-axis). Proteins above the diagonal line are higher in β3-WT ECs, whereas those below the line are higher in β3-HET ECs (n=3 samples per genotype). NRP1 is
present in both adhesomes (red circle). (D) FA-enriched EC samples were processed as in C and then analysed by western blot for the indicated proteins. A total
cell lysate (TCL) is shown for comparison. Data are representative of three independent experiments.
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found no obvious differences (Fig. 4A). We next immunolocalised
NRP1 in cells plated on FN overnight. Because of the VEGFdependence of our phenotypic angiogenic responses, we initially
concentrated on VEGF-stimulated cells. In β3-WT ECs, NRP1
localised to mature FAs, which were found at the ends of
filamentous actin (F-actin) fibres (Fig. 4B, left); as expected from
previous studies (Robinson et al., 2009), NRP1 also colocalised
with GFP-tagged β3-integrin in cDNA-expression-constructtransfected β3-WT ECs (Fig. 4B, middle). However, in VEGFstimulated β3-HET ECs, NRP1 no longer localised to these sites
(Fig. 4B, right).
To explore more precisely whether β3-integrin was required for
the initial recruitment of NRP1 to FAs, we plated cells on FN for
90 min, which allows mature, β3-integrin-rich, adhesions to form
(Schiller et al., 2011, 2013), and performed quantitative mass
spectrometry of the FA-enriched endothelial adhesome from β3-WT
and β3-HET ECs (Schiller et al., 2011) (Fig. 4C). For the present
study, we focused our attention on known adhesome proteins. β3and αv-integrins were, as expected, enriched in β3-WT adhesomes.
Although many differences were noted between the two genotypes,
the stoichiometry of many classical adhesome-related proteins (such
as β1-integrin, vinculin, talin and integrin-linked kinase) was
unchanged in β3-HET ECs. Most importantly, NRP1, as previously
reported by others (Kuo et al., 2011; Schiller et al., 2011), was
present within the adhesome of both genotypes. Immunoblotting of
FA-enriched cellular lysates confirmed this finding (Fig. 4D);
although the western blot (WB) signal for NRP1 was relatively
weak, it was present in both β3-WT and β3-HET ECs. Together,
these results suggest that β3-integrin is not essential for the initial
localisation of NRP1 to mature FAs, but, rather, regulates its
retention within FAs upon VEGF-stimulation.

β3-integrin directs NRP1’s control over FA remodelling

Given the noted changes in NRP1-dependent migration and retention
within FAs following an angiogenic stimulus, we next investigated
whether NRP1’s association with FA proteins in general was altered
in β3-HET ECs. We performed NRP1 immunoprecipitations on
lysates from β3-WT and β3-HET ECs followed by label-free
quantitative mass spectrometry, which highlighted a number of
previously demonstrated NRP1 co-associations such as myosin-9,
myosin-10 and filamin-A (Seerapu et al., 2013). Many VEGFinduced associations between NRP1 and FA-associated proteins
were similar between the two genotypes, but β3-HET cells showed a
number of significant changes in VEGF-induced interactions
between NRP1 and cytoskeletal proteins involved with cell
migration (Table 1), such as decreased interactions with filamin-A.
These observations, coupled with changes in NRP1’s mobilisation
away from mature FAs upon VEGF-stimulation, suggested that
NRP1-dependent changes in FA remodelling might be at the heart of
phenotypic differences between β3-WT and β3-HET cells.
Therefore, as a marker of FAs, we turned our attention to
examining interactions between NRP1 and PXN. As well as
demarcating FAs, PXN plays an important role in EC motility
and can be regulated by NRP1 (Raimondi et al., 2014).
Immunocytochemistry of cells plated overnight on FN showed a
predicted colocalisation of total PXN and NRP1 in non-VEGFstimulated β3-WT ECs. This colocalisation was maintained after
10 min of VEGF-stimulation (Fig. 5A). NRP1/PXN colocalisation
was also apparent in non-VEGF-stimulated β3-HET ECs, but it was
lost upon VEGF-stimulation. A similar pattern was observed in
β3-HET;NRP1Δcyto ECs, with β3-WT;NRP1Δcyto ECs showing
only a small loss of NRP1/PXN colocalisation after VEGFstimulation.

Table 1. Label-free quantitative mass-spectrometry analysis of NRP1-associated cytoskeletal-classed proteins

UNIPROT ID

Gene

WT −V

WT +V

HET −V

HET +V

Ratio WT+V/WT−V

Ratio HET+V/HET−V

Fold change HET/WT

Q6IRU2
P21107
P63260
P58771
Q6URW6
Q9QXS1
P47754
Q9WTI7
Q61879
E9QA15
Q9JHJ0
P63260
Q5RKN9
Q9JJ28
P68033
Q8BFZ3
P47757
Q8VDD5
P46735
E9Q634
Q8BTM8
P16546
Q9JMH9
P05213

Tpm4
Tpm3
Actg1
Tpm1
Myh14
Plec
Capza2
Myo1c
Myh10
Cald1
Tmod3
Actg1
Capza1
Flii
Actc1
Actbl2
Capzb
Myh9
Myo1b
LOC100504972
Flna
Spna2
Myo18a
Tuba1b

0.54
1.82
9.99
0.39
5.54
3.64
0.64
0.78
3.97
1.48
0.29
166.25
0.25
0.22
2.37
38.52
0.30
226.75
0.11
0.10
0.12
0.22
0.48
0.15

0.21
1.33
9.22
0.36
3.86
2.26
0.56
0.71
3.97
1.19
0.31
172.15
0.26
0.18
3.72
41.16
0.33
246.90
0.12
0.11
0.11
0.23
0.47
0.68

0.11
0.34
4.73
0.09
4.62
1.86
0.38
0.38
6.32
0.57
0.18
109.54
0.21
0.15
0.65
21.77
0.22
159.30
0.08
0.08
0.11
0.21
0.54
0.16

0.13
0.58
7.06
0.13
4.78
1.39
0.37
0.37
6.52
0.46
0.19
110.31
0.21
0.12
0.96
20.61
0.21
146.76
0.07
0.07
0.07
0.14
0.28
0.17

0.38
0.73
0.92
0.93
0.70
0.62
0.88
0.90
1.00
0.80
1.07
1.04
1.05
0.81
1.57
1.07
1.10
1.09
1.12
1.13
0.93
1.07
0.97
4.46

1.12
1.73
1.49
1.43
1.04
0.75
0.97
0.99
1.03
0.82
1.08
1.01
1.01
0.77
1.47
0.95
0.94
0.92
0.89
0.88
0.58
0.64
0.52
1.02

2.94
2.37
1.62
1.55
1.49
1.20
1.10
1.09
1.03
1.02
1.01
−1.03
−1.04
−1.05
−1.07
−1.13
−1.18
−1.18
−1.26
−1.28
−1.59
−1.67
−1.88
−4.36

The table shows a pared-down list of cytoskeletal-classed proteins that co-immunoprecipitated with NRP1 in β3-integrin wild-type (WT) and heterozygous
β3-integrin-deficient (HET) ECs in the presence (+V) or absence (–V) of VEGF-stimulation. Although they might be biologically relevant, for the sake of
confidence we have removed from the full list proteins that were only identified in one of the four samples or whose NRP1-normalised label-free quantification
(LFQ) values fell below 0.1. Highlighted in bold are previously reported interactions (Seerapu et al., 2013).
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Fig. 5. Paxillin activation and focal adhesion disassembly are sensitive to NRP1 disruption in β3-integrin-heterozygous endothelial cells. (A) ECs of the
indicated genotypes were seeded overnight on FN-coated glass coverslips. After 3 h of starvation, cells were treated ±VEGF for 10 min in serum-free medium,
then fixed and immunostained for total paxillin (PXN; green) and neuropilin-1 (NRP1; red). Split-channel close-ups are shown to depict PXN/NRP1 colocalisation.
Scale bar: 20 μm. The box and whisker plot shows Pearson’s correlation coefficient of PXN/NRP1 colocalisation in each of the indicated genotypes in the
indicated regions as determined using the ImageJ™ coloc2 plugin (means±interquartile ranges and extreme values; n≥5 cells per genotype, over ≥three
independent experiments). (B) Left panel: ECs of the indicated genotype were seeded overnight on FN. They were then starved for 3 h and treated ±VEGF for
10 min in serum-free medium. Cells were lysed and western blotted (WB) for levels of phosphorylated ( p) and total (t) PXN. GAPDH served as a loading control.
Data are representative of three independent experiments. Right panel: the graph shows densitometry of pPXN relative to tPXN, as determined by WB, over an
extended VEGF time course (means±s.e.m. from ≥three independent experiments). (C) ECs were seeded overnight onto FN-coated glass coverslips and stained
for pPXN. ECs were starved for 3 h and treated ±VEGF for 10 min in serum-free medium. Cells were fixed and immunostained for pPXN (green). Scale bar: 10 μm.
(D) ECs were transfected with a PXN-GFP construct and seeded at a low density on FN-coated coverslips. 72 h later, cells were starved and then treated with
VEGF in reduced-serum medium. Representative cells were then imaged live (every 2 min) on an inverted fluorescence microscope for 1 h to monitor focal
adhesion (FA) remodelling. The front and back ends of individual FAs were tracked over this period to measure FA assembly and disassembly, using the
ImageJ™ MTrack2 plugin. The box and whisker plot shows the rate of FA assembly or disassembly for each of the indicated genotypes (means±interquartile
ranges and extreme values; n≥20 FAs per genotype, from ≥two independent experiments). Asterisks indicate statistical significance: *P<0.05; **P<0.01; nsd, not
significantly different. Unpaired two-tailed t-test.

To pursue a potential β3-integrin-regulated NRP1 link with
PXN activation, we also analysed the phosphorylation of PXN
through tyrosine 118 by immunoblotting (Fig. 5B) and
immunocytochemistry (Fig. 5C), and found a substantial
reduction in PXN phosphorylation in β3-HET;NRP1Δcyto ECs,
but not β3-WT;NRP1Δcyto ECs, suggesting that PXN activation is
only NRP1-dependent when β3-integrin levels are suppressed.
Moreover, it seems that FA disassembly only becomes substantially
NRP1-dependent with reduced levels of β3-integrin: through the
live tracking of GFP-PXN in transfected cells (Fig. 5D), we

discovered that FA-assembly was faster in β3-HET, β3-WT;
NRP1Δcyto and β3-HET;NRP1Δcyto ECs compared to β3-WT
cells. Additionally, there was a trend toward increased FAdisassembly rates in β3-HET ECs. However, although FAdisassembly rates in β3-WT;NRP1Δcyto ECs were slightly
reduced compared to their β3-WT counterparts, FA-disassembly
rates were markedly retarded in β3-HET;NRP1Δcyto ECs,
illustrating the increased role for NRP1 in these cells.
Overall, our data suggest that, in the presence of β3-integrin, EC
migration is NRP1-independent; β3-integrin maintains NRP1 in
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FAs, thus ensuring a controlled migratory response to VEGFstimulation. Reduced levels of β3-integrin lead to changes in FA
remodelling and cell migration that are NRP1-dependent.
Simultaneous depletion of both endothelial β3-integrin and
NRP1 effectively inhibits already-established tumour growth
and angiogenesis

The identification of the mechanisms underlying increased
sensitivity to NRP1 disruption in ECs with reduced β3-integrin
expression should enable the rational design of intervention
strategies to improve anti-angiogenic outcomes in patients with
advanced cancers. To provide evidence in support of this idea, we
performed proof-of-concept studies in β3-integrin/NRP1-doublefloxed mice crossed to OHT-inducible-Pdgfb-iCreERT2 transgenics.
First, though, we confirmed the same mechanistic principle
described above in primary lung ECs acutely depleted of
β3-integrin (Fig. 6A). We observed NRP1 expression at the ends
of F-actin in OHT-treated β3-WT cells with and without VEGFstimulation, but not in the majority of OHT-treated β3-KO ECs after
VEGF treatment. We then initiated VEGF-induced microvessel
sprouting in aortic rings isolated from: (1) β3-floxed mice with and
without Pdgfb-iCreERT2; (2) NRP1-floxed mice with and without
Pdgfb-iCreERT2; or (3) double-floxed mice with and without PdgfbiCreERT2. OHT was administered to all rings after 4 days of
sprouting, and microvessels were enumerated 4 days later. Only in
rings from double-floxed Pdgfb-iCreERT2-positive animals was
further sprouting significantly inhibited (Fig. 6B). Finally, we
performed intervention CMT19T allograft studies by establishing
vascularised tumours in these same animals. After 10 days of growth,
all animals were administered OHT and tumours were allowed to
grow for another 10 days. In concordance with the intervention aortic
ring studies, further tumour growth and angiogenesis were
significantly inhibited in double-floxed Pdgfb-iCreERT2-positive
animals, but not in any of the other genotypes (Fig. 6C).
DISCUSSION

We previously showed that the total loss of β3-integrin expression
sensitises angiogenesis to NRP1 inhibition by siRNA or small
peptides (Robinson et al., 2009). This finding suggested to us, even
at the time, that an anti-angiogenic approach that simultaneously
targeted both molecules might offer therapeutic benefit to patients
with advanced cancers where traditional mono-target strategies
were largely failing; a concept strengthened further by our recent
findings demonstrating only transient inhibition of tumour growth
and angiogenesis after long-term depletion of endothelial β3integrin expression (Steri et al., 2014). Testing this notion, however,
requires that we have a deeper mechanistic understanding of, at the
very least, how the dual targeting affects its outcome. Achieving this
understanding necessitated moving away from β3-KO animals,
which are often criticised for sustaining angiogenesis through
developmental upregulation of VEGFR2, to a more subtle, albeit
global, alteration in β3-integrin expression – β3 heterozygosity.
Like their knockout counterparts (Robinson et al., 2009), β3-HET
mice display increased sensitivity to perturbations in NRP1
expression and we extend this finding to include NRP1 function,
as assayed through the deletion of its cytoplasmic tail. In marked
contrast to β3-KO animals, however, this phenomenon does not
occur through increased interactions in ECs between VEGFR2 and
NRP1 (Fig. 2). Rather, the work we present here guides us toward a
newly identified mechanism for β3-integrin function whereby it
regulates the retention of NRP1 within mature FAs upon VEGFstimulation (Fig. 5).
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AVEGFR2-independent role for NRP1 in regulating EC migration
is gaining ground. NRP1’s cytoplasmic domain is known to promote
FN fibrillogenesis in arterial ECs by regulating the trafficking of
activated α5β1-integrin (Valdembri et al., 2009), and NRP1 is
involved in ABL1-mediated PXN activity in human dermal ECs
(Raimondi et al., 2014) on FN. Crucially, however, here we report that
NRP1’s involvement in EC migration, at least in microvascular ECs,
is regulated by β3-integrin. Endothelial NRP1 seems to play no role in
pathological angiogenesis in β3-WT mice (Figs 1 and 6). Although
this idea has been alluded to in a number of studies (Fantin et al.,
2011, 2013; Lanahan et al., 2013; Robinson et al., 2009), we fully
extend this conclusion to primary tumour growth and angiogenesis. In
the models that we have employed, we demonstrate, categorically, that
NRP1 perturbations alone do not disrupt pathological angiogenesis.
When coupled to reductions in β3-integrin levels, however, NRP1’s
participation in angiogenesis becomes essential. Equally, reductions
in β3-integrin expression without concomitant changes in NRP1 do
not drastically alter tumour angiogenesis (particularly in alreadyestablished tumours). This suggests that there is redundancy built into
the system such that the presence of either molecule in mature FAs is
sufficient to mediate adequate PXN activity.
We hypothesise a default system in wild-type microvascular ECs
in which αvβ3-integrin’s molecular associations at mature FAs
predominate and prevent NRP1 from fully participating in FA
dynamics. αvβ3-integrins are known to immobilise in static FAs
(Zamir et al., 2000) and it seems that they help to sequester NRP1 at
these sites, even after VEGF-stimulation, which prevents it from
activating PXN. In contrast, the long-term suppression of β3integrin triggers an escape pathway whereby PXN activation and
EC migration become dependent on NRP1 function; mobilisation of
NRP1 away from mature/static FAs allows it to direct PXN activity
(Fig. 6D). The idea of differential FA dynamics dependent on which
integrin subclasses are engaged with an FN-rich ECM is not a new
concept (see Truong and Danen, 2009, for example). However, this
is the first time that differential NRP1 localisation and function have
been linked to these changes.
The role that NRP1 plays in mediating VEGF-induced ERK
phosphorylation seems to be controversial and dependent on the EC
source and method employed to elicit NRP1 inhibition. Although Pan
et al. (2007) found that anti-NRP1 monoclonal antibodies (mAbs)
had no effect on VEGF-dependent ERK phosphorylation in human
umbilical vein endothelial cells (HUVECs), Murga et al. (2005)
demonstrated reduced VEGF-induced ERK phosphorylation in these
cells after NRP1 siRNA knockdown. Lanahan et al. (2013) found that
the loss of NRP1’s cytoplasmic tail reduced VEGF-dependent ERK
phosphorylation in both heart and arterial ECs. Raimondi et al.
(2014) report that NRP1 siRNA knockdown impairs ERK
phosphorylation in human dermal microvascular endothelial cells
(HDMECs). We report here that the deletion of NRP1’s cytoplasmic
tail does not affect VEGF-induced ERK phosphorylation in WT
microvascular ECs (Fig. 2). These apparent discrepancies need
addressing and are the focus of ongoing research in our laboratory.
It is particularly important to address these discrepancies given
our finding that β3-integrin’s regulation of NRP1 function is
dependent on the presence of VEGF, even when NRP1’s regulation
of VEGFR2 is unchanged. This is important clinically because it
provides a therapeutic opportunity to enhance the efficacy of current
strategies that largely focus on manipulating the VEGF-VEGFR2
pathway, which is linked with significant side-effects and prone to
treatment resistance (Ebos and Kerbel, 2011). We now have the
chance to affect VEGF-dependent angiogenesis in an apparently
VEGFR2-independent manner.
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Fig. 6. Simultaneously depleting both β3-integrin and
NRP1 blocks growth and angiogenesis in alreadyestablished tumours. (A) Primary lung microvascular ECs
were isolated from β3-floxed-Pdgfb-iCreERT2-negative and
-positive animals. Tamoxifen (OHT) was administered after
pure EC populations were achieved. Cells were then plated
overnight on FN-coated glass coverslips. Cells were starved
for 3 h and then treated ±VEGF for 10 min in serum-free
medium. Cells were fixed and stained with phalloidin for
F-actin (green), and immunostained for NRP1 (red). White
arrows point to the ends of actin filaments. Scale bar: 20 μm.
The bar chart shows the percentage of cells within the
population showing NRP1 staining at the end of actin
filaments (mean+s.e.m.; n≥50 cells per condition).
(B) Microvessel sprouting of aortic ring explants of the
indicated genotypes. Protein knockout in ECs was induced in
culture with 1 μM OHT 4 days after VEGF-induced sprouting
had been established. The bar chart shows the total number
of microvessel sprouts per aortic ring after an additional
4 days of VEGF-stimulation (mean+s.e.m. from three
independent experiments; n≥40 rings per genotype). (C)
Tumour growth and angiogenesis were measured in animals
of the indicated genotypes. Mice were injected
subcutaneously with CMT19T cells and 10 days later OHT
was administered. After an additional 10 days (20 days in
total) tumours were harvested. Upper panel: the bar chart
shows mean tumour volumes measured at days 10 and 20
(+s.e.m. of two or more independent experiments; n≥10
animals per genotype). The western blot to the right shows
representative depletion of β3-integrin and NRP1 in tumour
endothelial cells (TECs) isolated from Cre-positive animals,
compared to Cre-negative littermate controls. Bottom panel:
blood-vessel density in 20-day tumours was assessed by
counting the total number of endomucin-positive vessels
around the periphery (within 150 μm of the edge of the
tumour) of midline bisected tumour sections. The bar chart
shows mean vessel number per mm2 (+s.e.m.).
Representative micrographs of endomucin staining (red) are
shown below. Scale bar: 50 μm. Asterisks indicate statistical
significance: *P<0.05; ***P<0.001; nsd, not significantly
different. Unpaired two-tailed t-test. (D) Schematic
representation of the hypothesised participation of NRP1 in
focal adhesion (FA) remodelling and migration in β3-WT (left)
and β3-suppressed (right) ECs. ITGN, integrin.
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This study provides proof-of-concept that a dual-combative
αvβ3-integrin/NRP1 targeting approach offers a clinically
beneficial way of treating advanced solid cancers. Small-molecule
inhibitors directed against NRP1 are currently under development
and we hope that these can soon be tested alongside existing or new
αvβ3-integrin antagonists, with the caveat that both molecules are
expressed by multiple cell types that contribute to tumour growth
and angiogenesis, including platelets, and off-target (i.e. non-EC)
effects will have to be examined carefully; although we can rule out
their contribution to the EC-double-KO intervention studies
(Fig. 6), these other cells types might be contributing to β3-HET
angiogenic responses. Nonetheless, we provide a strong
mechanistic foundation for understanding the molecular basis of
how a dual-targeted approach against these two endothelial
molecules might meet with success. This will allow us, in the
meantime, to more fully explore the long-term durability of such an
approach when applied to additional clinically relevant scenarios.
Moreover, detailed further analysis and extension of our mass
spectrometric studies in ECs will allow us to fully explore how
differential adhesion dynamics, mediated by distinct integrin-ECM
interactions, result in the formation of unique signalling platforms
that can be exploited to manipulate angiogenic responses.
MATERIALS AND METHODS
Reagents

VEGF-A164 was made in-house according to the method published by
Krilleke et al. (2007). All chemicals were from Sigma-Aldrich (Poole, UK)
unless otherwise indicated.
Animals

All animals were on a mixed C57BL6/129 background. Littermate controls
were used for all in vivo experiments. All animal experiments were
performed in accordance with UK Home Office regulations and the
European Legal Framework for the Protection of Animals used for
Scientific Purposes (European Directive 86/609/EEC).
In vivo tumour growth assays

Mouse melanoma (B16F0, ATCC; mycoplasma free) or mouse lung
carcinoma (CMT19T, CR-UK Cell Production; mycoplasma free) cells
(1×106) were injected subcutaneously in the flank of experimental and
littermate-control mice. 12-20 days after injection, mice were killed, tumour
sizes measured and tumour samples were fixed in 4% paraformaldehyde for
histological analysis. For prevention studies in Pdgfb-iCreERT2 mice
(Fig. 1, supplementary material Fig. S1), slow release (5 mg, 21-day release)
tamoxifen pellets (Innovative Research of America, Sarasota, FL) were
implanted subcutaneously into the scruff of the neck 3 days prior to tumour
cell injection. For intervention studies (Fig. 6), pellets were implanted after
10 days of initial tumour growth. Tumour volumes were calculated
according to the formula: length×width2×0.52.
Immunohistochemical analysis of tumour sections

At 24-h post-fixation, tumours were bisected at the midline and embedded in
paraffin (cut face toward blade) and 5-μm sections were prepared.
Immunostaining was then performed with sodium-citrate antigen retrieval
as described previously (Reynolds et al., 2002). Images were acquired on an
Axioplan (Zeiss, Cambridge, UK) epifluorescent microscope and tissue area
was quantified using ImageJ™ software available at the National Institutes
of Health website. Primary antibodies were: rat anti-endomucin (clone
V.7C7, used at 1:500, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit
anti-CD146 (clone EPR3208, used at 1:500, Abcam, Cambridge, UK).
Secondary antibodies were: donkey anti-rat Alexa-Fluor®-594 and donkey
anti-rabbit Alexa-Fluor®-488 conjugates (Invitrogen, Paisley, UK), both
used at 1:500.
Blood-vessel density was assessed by counting the total number of
endomucin-positive vessels per mm2 across entire midline tumour sections
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from age-matched, size-matched tumours. For tumour sections from the
intervention studies (Fig. 6), vessels around the perimeter of the sections
were counted in order to avoid the necrotic centres of tumours.
Mouse tumour endothelial cell isolation

Tumour ECs were isolated and analysed by western blot as previously
described by Steri et al. (2014).
Ex vivo aortic ring assay

Thoracic aortae were isolated from 6- to 9-week-old adult mice and prepared
for culture as described extensively by Baker et al. (2012). Protein knockout
in ECs was induced in culture with 1 μM 4-hydroxytamoxifen (OHT).
Where indicated, VEGF was added at 30 ng/ml. Microvessel growth
of aortic rings was quantified after 6-10 days. For the intervention study,
protein knockout in ECs was induced in culture with 1 μM OHT 4 days after
VEGF-induced sprouting had been established, and the microvessel sprouts
were quantified after an additional 4 days of VEGF-stimulation.
Mouse lung microvascular endothelial cell isolation and culture

Primary mouse lung ECs were isolated from adult mice as described
previously by Reynolds and Hodivala-Dilke (2006). To induce target gene
deletion in Pdgfb-iCreERT2-floxed cell lines, cells were grown for 48 h in
medium supplemented with 500 nM OHT.
For immortalisation, cells were treated with polyoma-middle-T-antigen
(PyMT) retroviral transfection as described previously by Robinson et al.
(2009). Briefly, PyMT conditioned medium was collected, filter sterilised
using a 0.45 μm filter, and stored at −80°C until use. Following two rounds
of CD102-positive selection, primary ECs in six-well plates were treated
with the preserved PyMT conditioned medium supplemented with 8 μg/ml
polybrene for 6 h at 37°C. PyMT conditioned medium was removed and
replaced with complete growth medium. This same procedure was repeated
the following day. Cells were observed and passaged for 4 weeks to ensure
their immortalisation. Subsequently, they were maintained in a 1:1 mixture
of DMEM low glucose:Ham’s F12 nutrient mixture (Invitrogen)
supplemented with 0.1 mg/ml heparin and 10% FBS, and used between
passages 5-20. Cells were routinely checked by flow cytometry for surface
expression of ICAM2, CD31 and VECAD (see supplementary material
Fig. S3) to ensure that they retained their normal EC characteristics. Cells
were also routinely checked for their ability to survive extended periods of
confluency, which indicates absence of transformation (May et al., 2005).
For experimental analyses, tissue culture plates and flasks were coated
overnight at 4°C with one or more of the following, as specified below: 0.1%
gelatin (type A from porcine skin, ∼300 g bloom), Purecol (COLI) (Nutacon
B.V., The Netherlands), human plasma fibronectin (FN) (Millipore,
Watford, UK) and mouse multimeric vitronectin (VN) (Patriecell Ltd,
Nottingham, UK).
Western blot analysis

For the analysis of VEGFR2, NRP1, β3-integrin, ERK1/2, p130cas and
FAK, ECs were seeded at 2×105 cells per well in six-well plates coated with
0.1% gelatin, 10 μg/ml FN, 10 μg/ml COLI and 2 μg/ml VN. For paxillin
analysis, ECs were seeded at the same density, but on plates coated with only
10 μg/ml FN in PBS. 24 h later, cells were starved for 3 h in serum-free
medium (OptiMEM®; Invitrogen). VEGF was then added to a final
concentration of 30 ng/ml and cells were lysed at the indicated times (see
main text) in EB (3% SDS, 60 mM sucrose, 65 mM Tris-HCl pH 6.8).
15-30 μg of protein from each sample was loaded onto 8-10%
polyacrylamide gels. For paxillin analysis, samples were loaded onto a
4-12% gradient gel for better resolution. The protein was transferred to a
nitrocellulose membrane and incubated for 1 h in 5% milk powder/PBS
plus 0.1% Tween-20 (PBSTw), followed by an overnight incubation in
primary antibody diluted 1:1000 in 5% bovine serum albumin (BSA)/
PBSTw at 4°C. The blots were then washed 3× with PBSTw and incubated
with the relevant horseradish peroxidase (HRP)-conjugated secondary
antibody (Dako) diluted 1:2000 in 5% milk/PBSTw, for 1 h at room
temperature. Chemiluminescence was detected on a Fujifilm LAS-3000
darkroom (Fujifilm UK Ltd, Bedford, UK). Antibodies (all used at 1:1000
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and purchased from Cell Signaling Technology, unless noted otherwise)
were: anti-phospho (Y1175) VEGFR2 (clone 19A10); anti-VEGFR-2
(clone 55B11); anti-Neuropilin-1 (cat. no. 3725); anti-β3-integrin (cat. no.
4702); anti-phospho (Thr202/Tyr204) p44/42 MAPK Erk1/2 (clone
D13.14.4E); anti-total p44/42 MAPK Erk1/2 (clone 137F5); anti-phospho
(Y410) p130cas (cat. no. 4011); anti-p130cas (cat. no. 610271, BD
Biosciences, Oxford); anti-phospho (Y407) FAK (#OPA1-03887,
ThermoScientific); anti-FAK (cat. no. 3285); anti-HSC70 (clone B-6,
Santa Cruz Biotechnology); anti-phospho (Y118) paxillin (cat. no. 2541);
anti-paxillin (ab32084; Abcam); anti-GAPDH (14C10, cat. no. 2118); antiSP1 (cat. no. 5931); anti-histone H3 (D1H2, cat. no. 4499); anti-vimentin
(D21H3, cat. no. 5741).
Flow cytometry

For flow-cytometric analysis, cells were trypsinised, resuspended in FACS
buffer (1% FBS in PBS+1 mM CaCl2+1 mM MgCl2) and labelled with one
of the following antibodies (all used at 1:200 and, unless stated otherwise,
purchased from eBioscience, Hatfield, UK): PE-anti-mouse Flk1, PE-antimouse CD49a (Cambridge Bioscience, Cambridge, UK); PE-anti-mouse
CD49b; PE-anti-mouse CD49e; PE-anti-mouse CD51; PE-anti-mouse
CD29; PE-anti-mouse CD61; PE-anti-mouse integrin beta 5; PE-antimouse CD31; FITC-anti-mouse ICAM2; PE-anti-mouse VECAD;
appropriate PE/FITC-labelled isotype-matched controls were from
eBioscience. In the case of Flk1 analysis, cells were stimulated with
30 ng/ml VEGF at 37°C over a 60-min time course before trypsinisation.
Immunoprecipitation assay

Cells were grown to 80-90% confluency in 15-cm dishes coated with
10 μg/ml FN in PBS. After starvation in OptiMEM® for 3 h, cells were
stimulated with 30 ng/ml VEGF for 10 min (+VEGF), or for the indicated
times, at 37°C. Cells were then placed on ice, washed two times with PBS,
and lysed in 0.5 ml/plate of RIPA buffer (20 mM Tris pH 7.4, 50 mM NaCl,
0.1% SDS, 1% Triton, 1% Deoxycholate, 1% NP40) containing PMSF
(∼1 mM) and Halt® Protease and Phosphatase inhibitor (1:100). Lysates
were centrifuged at 12,000 g for 10 min at 4°C. 400 μg of total protein from
each sample was immunoprecipitated by incubating them with protein-G
Dynabeads® (Invitrogen) coupled to a rabbit-anti-mouse-VEGFR2
antibody (clone 55B11, Cell Signaling Technology) for the VEGFR2
immunoprecipitation (IP), or a goat anti-mouse Neuropilin-1 antibody
(AF566, R&D Systems) for the NRP1 IP, on a rotator overnight at 4°C.
Immunoprecipitated complexes were washed three times with 0.2 ml
of RIPA buffer, and once in PBS, before being added to, and boiled in,
1× NuPAGE® sample reducing agent (Life Technologies), ready for
western blotting or mass spectrometry analysis.
Adhesion assays
Static adhesion

96-well plates were coated overnight at 4°C with 10 μg/ml COLI, 10 μg/ml
FN, 10 μg/ml laminin-I (LN) or 2 μg/ml VN in PBS, or a mixture (MIX)
containing 10 μg/ml COLI, 10 μg/ml FN and 2 μg/ml VN in 0.1% gelatin
was also used. The wells were then washed with PBS, and blocked for 1 h at
room temperature (RT) with 1% BSA in PBS, before a final wash in PBS.
Prior to seeding, cells were starved for 3 h in Opti-MEM®, trypsinised and
resuspended in serum-free OptiMEM®. They were then seeded in serumfree OptiMEM® at a concentration of 1×104 cells/well for 90 min at 37°C.
Plates were washed three times gently by immersion in a bucket of PBS, and
any excess volume was removed. Wells were stained with methylene blue
for 30 min, washed for 15 min under running water and air-dried. Dye was
extracted with 50% ethanol:50% 0.1 N HCl and the absorbance of each well
was measured at 610 nm.
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90 min at 37°C. Plates were tapped vigorously on the bench top and wells
were washed thoroughly using a multi-channel pipette. Wells were stained
with methylene blue for 30 min, washed for 15 min under running water and
air-dried. Dye was extracted with 50% ethanol:50% 0.1 N HCl and the
absorbance of each well was measured at 610 nm.
Random-migration assay

ECs were starved in OptiMEM® for 3 h, trypsinised and seeded at 1.5×104
cells/well in 24-well plates coated with 10 μg/ml FN in PBS, and allowed to
adhere for 3 h. The media was then replaced with OptiMEM®+2% FBS, and
half of the wells were supplemented with 30 ng/ml VEGF. One phasecontrast image/well was taken live every 10 min in a fixed field of view
using an inverted Axiovert (Zeiss) microscope for 15 h at 37°C and 4%
CO2. Individual cells were then manually tracked using the ImageJ™ cell
tracking plugin, and the speed of random migration was calculated in μm
moved/hour.
Wound-closure assay

ECs were seeded at 4×105 cells/well in six-well plates coated with 10 μg/ml
FN in PBS, and cultured until the next day, by which time they had reached
confluency. Cells were serum starved for 3 h in OptiMEM® before
scratching the confluent monolayer with a P200 pipette tip. Phase-contrast
images of scratches were then captured and the media was changed to
OptiMEM® containing 30 ng/ml VEGF. After 24 h, cells were fixed for
10 min with 4% formaldehyde and scratches were imaged again. The degree
of scratch-wound closure was quantified by measuring the gap between cells
in three areas per field using Axiovision (Zeiss) software, taking an average,
and calculating the length of change between time points.
Immunocytochemistry

Either primary or immortalised ECs were seeded at 1.5×105 cells/well in sixwell plates on acid-washed and oven-sterilised glass coverslips, coated with
10 μg/ml FN in PBS and cultured until the next day. Cells were starved for
3 h in serum-free OptiMEM®, and either stimulated with 30 ng/ml VEGF at
37°C for 10 min (+VEGF), or not at all (−VEGF). Cells were then fixed in
4% formaldehyde for 10 min, washed in PBS, permeabilised with 0.5%
NP40 in PBS, blocked in 0.1% BSA+0.2% Triton in PBS, and incubated
with primary antibody diluted 1:100 in PBS for 1 h at RT. After further PBS
washes, cells were incubated with the relevant Alexa-Fluor®-conjugated
secondary antibody (Invitrogen) diluted 1:500 in PBS for 45 min at RT.
Coverslips were washed in PBS again before they were mounted on slides
with Prolong® Gold containing DAPI (Invitrogen). To stain for filamentous(F) actin, Alexa-Fluor®-568–phalloidin (Invitrogen) was used 1:300 in PBS
at the secondary-antibody incubation stage. To look at β3-integrin
fluorescently, 1×106 ECs were transfected with a GFP-tagged β3-integrin
cDNA expression construct ( provided by Dr Maddy Parsons, King’s
College London, London, UK) by nucleofection prior to seeding on
coverslips at 1.5×105 cells/well. Antibodies (all used at 1:100) were: antiphospho (Y118) paxillin (Cell Signaling Technology, cat. no. 2541); antipaxillin (ab32084, Abcam); anti-neuropilin-1 (AF566, R&D Systems).
NRP1-PXN colocalisation was quantified using the Coloc2 ImageJ™
plugin to determine the Pearson’s correlation coefficient.
Cell fractionation assay

ECs were seeded in plates coated with 0.1% gelatin, 10 μg/ml FN, 10 μg/ml
COLI and 2 μg/ml VN. 24 h later, cells were starved for 3 h in serum-free
OptiMEM®, and either stimulated with 30 ng/ml VEGF or not. Cells were
then trypsinised and centrifuged at 500 g. Cell fractionation was carried out
following the ‘Subcellular protein fractionation kit for cultured cells’
(ThermoScientific) protocol exactly, and samples were prepared for western
blotting.

Adhesion on various matrix concentrations

96-well plates were coated overnight at 4°C with serial dilutions of VN or
FN. The wells were then washed with PBS, and blocked for 1 h at RT with
1% BSA in PBS. Prior to seeding, cells were starved for 3 h in Opti-MEM®,
trypsinised and resuspended in serum-free OptiMEM®. They were then
seeded in serum-free Opti-MEM® at a concentration of 3×104 cells/well for

Focal-adhesion enrichment

ECs were starved in serum-free OptiMEM® for 3 h and seeded at 6×106
cells/plate in 10-cm plates that were previously coated with 10 μg/ml FN in
PBS overnight at 4°C and blocked in 1% BSA in PBS for 1 h at RT. Cells
were allowed to adhere for 90 min to allow for mature FAs to form and either
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stimulated with 30 ng/ml VEGF at 37°C for 10 min (+VEGF) or not at all
(−VEGF). Cells were washed in PBS+1 mM CaCl2+1 mM MgCl2 (PBS++)
and incubated with 0.5 mM Dithiobis(succinimidyl propionate) (DSP) and
0.05 mM 1,4-di-[30-(20-pyridyldithio)-propionamido] butane (DPP)
diluted in PBS++ for 5 min to cross-link FAs to the plate. This reaction
was quenched with 1 M Tris-HCl pH 7.5 before cells were lysed in RIPA for
30 min on ice with occasional agitation. RIPA was collected without
scraping, and the plates were blasted with a high-sheer flow jet of distilled
water to remove cell debris. Cross-linked proteins were eluted with 2 ml
dithiothereitol (DTT) buffer (25 mM Tris-HCl pH 7.5, 10 mM NaCl,
0.1% SDS, 100 mM DTT) for 1 h at 60°C in a sealed and humidified
chamber. 8 ml of acetone was added to this solution and left overnight at
−20°C to allow the proteins to precipitate. Samples were then centrifuged at
13,000 g for 40 min, and the acetone layer removed. The pellet was
resuspended in EB (see above) ready for western-blot or mass-spectrometry
analysis.
Focal-adhesion tracking

1×106 ECs were transfected with a GFP-tagged paxillin cDNA expression
construct (kindly provided by Dr Maddy Parsons, King’s College London,
London, UK) and a fraction of these were seeded on acid-washed and ovensterilised glass coverslips, coated with 10 μg/ml FN in PBS, in wells of a
six-well plate. Cells were cultured for ∼48 h before they were starved in
serum-free OptiMEM® for 3 h. In turn, individual coverslips were
separately transferred to OptiMEM®+2% FBS and 30 ng/ml VEGF was
added. An Axiovert (Zeiss) inverted microscope was then used to take live
images of the GFP-paxillin-positive focal adhesions in a selected field of
view every 2 min for 1 h at 37°C+4% CO2. Assembly and disassembly was
quantified by manually tracking leading and trailing edges of FAs using the
MTrackJ plugin for ImageJ™.
Mass-spectrometry analysis

Mass spectrometry was carried out by the Fingerprints Proteomics Facility,
Dundee University, Dundee, UK as per Schiller et al. (2011). Peptides were
identified and quantified using MaxQuant software using the Andromeda
peptide database. To achieve label-free quantitative results, three biological
repeats were pooled and each of these pooled samples was analysed via three
technical repeats through the spectrometer.
Statistical analysis

Significant differences between means were evaluated by Student’s t-test.
P<0.05 was considered statistically significant. For flow cytometric analysis
of integrins, relative differences were deemed significant if they were greater
than twofold.
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